ISCOMs (immunostimulating complexes): The first decade

Immunology and Cell Biology

Volumn 74, Issue 1, 1996, Pages 8-25

  Barr, Ian G ^a   Mitchell, Graham F ^a  

^a CSL LIMITED   (Australia)

Author keywords

adjuvants; immune response; immunization; ISCOMs; vaccine

Indexed keywords

ADJUVANT; CANCER VACCINE; HEPATITIS A VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; ISCOM; LIPID; MALARIA VACCINE; MELANOMA VACCINE; PHOSPHOLIPID; QUIL A; SAPONIN; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; INFLUENZA; MALARIA; REVIEW; VACCINATION;

EID: 0029879995     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.2     Document Type: Review

References (152)

1. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457-60.
2. Shaw Warren H. Adjuvants. In: Roitt IM (ed.), Encyclopedia of Immunology. London: Academic Press. 1992; 28.
3. Kersten GFA, Teerlink T, Derks HJGM et al. Incorporation of the major outer membrane protein of Neisseria Gonorrhoea in saponin-lipid complexes (iscoms): Chemical analysis, some structural features and comparison of their immunogenicity with other antigen delivery systems. Infec. Immun. 1988; 56: 432-8.
4. Höglund S, Dalsgaard K, Lövgren K, Sundquist B, Osterhaus A, Morein B. Iscoms and immunostimulation with viral antigens. Subcellular Biochemistry 1989; 15: 39-68.
5. Özel M, Höglund S, Gelderblom H, Morein B. Quarternary structure of the immunostimulating complex (ISCOM). J. Ultrastruc. Mol. Struc. Res. 1989; 102: 240-8.
6. Kersten G. Aspects of ISCOMS. Analytical, pharmaceutical and adjuvant properties. PhD Thesis, University of Utrecht, 1990.
7. Sundquist B, Lovgren K, Höglund S, Morein B. Influenza virus iscoms: Biochemical characterization. Vaccine 1988; 6: 44-58.
8. Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol. Appl. Biochem. 1988; 10: 161-72.
9. Horzinck M, Mussgay M. Studies on the substructure of togaviruses. Effect of urea, deoxycholate and saponin on the Sinbus virion. Arch. Gesamte. Virusforsch. 33: 296-305.
10. Kersten GFA, Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. Bioch. Biophys. Acta 1995; 1241: 117-38.
11. Morein B, Lövgren K, Höglund S, Sundquist B. Iscom: An immunostimulating complex. Immunol. Today 1987; 8: 333-8.
12. Claassen I, Osterhaus A. The iscom structure as an immune enhancing moiety: Experiences in viral systems. Res. Immunol. 1992; 143: 531-41.
13. Morein B, Lövgren K, Rönnberg B, Sjolander A, Villacrés-Erikson M. Immunostimulating complexes. Clinical potential in vaccine development. Clin. Immunother. 1995; 3: 461-75.
14. Rimmelzwaan GF, Osterhaus ADME. A novel generation of viral vaccines based on the ISCOM matrix. In: Powell MF, Newman MJ (ed.) Vaccine Design. The Subunit and Adjuvant Approach. New York: Plenum Press, 1995; 543-58.
15. Ramon G. Procedes pour accroitre la production des antitoxines. Ann. Inst. Pasteur, Paris 1926; 40: 1-10.
16. Espinet R.G. Nuevo tipo de vacuna antiaftosa a complejo glucovirico. Gac. Vet. 1951; 74: 1-13.
17. Dalsgaard K. Thin layer chromatographic fingerprinting of commercially available saponins. Dan. Tidsskr. Farm. 1970; 44: 327-31.
18. Dalsgaard K. Saponin adjuvants III. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in foot-and-mouth disease vaccines. Arch. Gesamte Virusforsch 1974; 44: 243-54.
19. Dalsgaard K, Jensen MH. Saponin adjuvants. Part 6. The adjuvant activity of Quil A in trivalent vaccination of guinea pigs against foot-and-mouth disease. Acta Vet. Scand. 1977; 18: 367-73.
20. Dalsgaard K. A study of the isolation and characterization of the saponin Quil A. Acta Vet. Scan. Suppl. 1978; 69: 1-40.
21. Higuchi R. Structure of the desacylsaponins obtained from the bark of Quillaja saponaria. Phytochem. 1987; 26: 229-35.
22. Higuchi R, Tokimitsu Y, Komori T. An acylated triterpenoid saponin from Quillaja saponaria. Phytochem. 1988; 27: 1165-8.
23. Kensil C, Patel C, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991; 146: 431-7.
24. Soltysik S, Bedore DA, Kensil CR. Adjuvant activity of QS-21 isomers. Ann. New York Acad. Sci. 1993; 690: 392-5.
25. Bomford R, Stapleton M, Winsor S et al. Adjuvanticity and iscom formation by structurally diverse saponins. Vaccine 1992; 10: 572-7.
26. Dourmashkin RR, Dougherty RM, Harris RJC. Electron microscopic observations of Raus sarcoma virus and cell membranes. Nature 1962; 194: 1116-9.
27. Bangham AD, Home RW. Action of saponin on biological cell membranes. Nature 1962; 196: 952-3.
28. Glauert AM, Dingle JT, Lucy JA. Action of saponin on biological cell membranes. Nature 1962; 196: 953-5.
29. Lucy JA, Glauert AM. Structure and assembly of macromolecular lipid complexes composed of globular micelles. J. Mol. Biol. 1964; 8: 727-48.
30. Morein B, Lövgren K, Höglund S, Sundquist B. Iscom: An immunostimulating complex. Immunol. Today 1987; 8: 333-8.
31. Kersten GFA, Spiekstra A, Beuvery EC, Crommelin DJA. On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochem. Biophys. Acta 1991; 1062: 165-71.
32. Rönnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM-Matrix. Vaccine 1995; 13: 1375-82.
33. Morein B, Simons K. Subunit vaccines against enveloped viruses: Virosomes, micelles and other protein complexes. Vaccine 1985; 3: 83-93.
34. Kyte J. Membranes. In: Structure in Protein Chemistry. New York: Garland Publishing 1995; 527-31.
35. Mougin B, Bakouche O, Gerlier D. Humoral Immune response elicited in rats by measles viral membrane antigens presented in liposomes and iscoms. Vaccine 1988; 6: 445-8.
36. Trudel M, Nandon F, Séguin C, Boulay G, Lussier G. Vaccination of rabbits with a bovine herpes virus type 1 subunit vaccine: Adjuvant effect of iscoms. Vaccine 1987; 5: 239-43.
37. Merza M, Belak S, Morein B. Characterization of an iscom prepared with envelope glycoproteins of bovine herpesvirus type 1. J. Vet. Med. B. 1988; 35: 695-703.
38. Pyle S, Morein B, Bess J et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein. Vaccine 1989; 7: 465-73.
39. Trudel M, Nandon F, Séguin C., Simard C, Lussier G. Experimental polyvalent iscom subunit vaccine antibodies that neutralize human and bovine respiratory syncytial virus. Vaccine 1989; 7: 12-16.
40. Åkerblom L, Nara P, Dunlop N, Putney S, Morein B. HIV experimental vaccines based on the iscom technology using envelope and gag gene products. Biotechnol. Therapeu. 1993; 4: 145-61.
41. Rimmelzwaan GF, Siebelink HJ, Huisman C, Moss B, Francis MJ, Osterhaus ADME. Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of surface glycoprotein in immune stimulating complexes. J. Gen. Virol. 1994; 75: 2097-102.
42. Uggla A, Araujo FG, Lundén A, Lövgren K, Remmington J, Morein B. Immunizing effect in mice of two Toxoplasma gondii iscom preparations. J. Vet. Med. B. 1988; 35: 311-14.
43. Morein B, Ekström J, Lövgren K. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J. Immunol. Methods 1990; 128: 177-81.
44. + cytotoxic T lymphocytes towards soluble antigens: Immunostimulating ovalbumin complexes enter and allow sensitisation against the immundominant peptide. Eur. J. Immunol. 1991; 21: 1523-7.
45. Mowat A, Donachie MCI, Reid G, Jarret O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunol. 1991; 72: 317-22.
46. Reid G. Soluble proteins incorporate into iscoms after covalent attachment of fatty acid. Vaccine 1992; 10: 597-602.
47. Browning M, Reid GR, Osborne R, Jarret O. Incorporation of soluble antigens into iscoms: HIV gp120 iscoms induce virus neutralizing antibodies. Vaccine 1992; 10: 585-90.
48. Kazanji M, Laurent F, Péry P. Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeira falciformis in iscoms. Vaccine 1994; 12: 798-804.
49. Weiss HP, Stitz L, Becht H. Immunogenic properties of ISCOMs prepared with influenza virus glycoprotein. Arch. Virol. 1990; 114: 109-20.
50. Pedersen IR, Bøg-Hansen TC, Dalsgaard K, Heegaard PMH. Iscom immunization with synthetic peptides representing measles virus hemagglutinin. Virus Res. 1992; 24: 145-69.
51. Weijer K, Pfauth A, van Herwijnen R et al. Induction of feline leukaemia virus-neutralizing antibodies by peptides derived from the FeLv env gene. Vaccine 1993; 11: 946-56.
52. Lövgren K, Lindmark J, Pipkorn R, Morein B. Antigenic presentation of small molecules and synthetic peptides conjugated to a preformed iscom as carrier. J. Immunol. Methods 1987; 98: 137-43.
53. Sjölander A, Lövgren K, Ståhl S et al. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. Vaccine 1991; 9: 443-50.
54. Larsson M, Lövgren K, Morein B. Immunopotentiation of synthetic oligopeptides by chemical conjugation to ISCOMs. J. Immunol. Methods 1993; 162: 257-60.
55. Lövgren K, Larsson M. Conjugation of synthetic peptides to carrier ISCOMs: Factors affecting the immunogenicity of the conjugate. J. Immunol. Methods 1994; 173: 237-43.
56. Merza M, Linné T, Höglund S, Portetelle D, Burny A, Morein B. Bovine leukemia virus iscoms: Biochemical characterization. Vaccine 1989; 7: 22-8.
57. Varsanyi TM, Morein B, Löve A, Norrby E. Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the haemagglutinin or fusion protein. J. Virol. 1987; 61: 3896-901.
58. Teerlink T, Beuvry EC, Evenberg D, van Wezel TL. Synergistic effect of detergent and aluminium phosphate on the humoral immune response to bacterial and viral membrane proteins. Vaccine 1987; 5: 307-13.
59. Berezins VE, Zaides VM, Isaeva ES, Artamonov AF, Zhdanov VM. Controlled organisation of multimolecular complexes of envelope glycoproteins: Study of immunogenicity. Vaccine 1988; 6: 450-6.
60. Russell PH, Hock G. Local and antibody forming cell responses to the Hitchner B1 and Ulster strains of Newcastle Disease virus. Vet. Immunol. Immunopath. 1993; 37: 165-80.
61. Ertürk M, Jennings R, Hockley D, Potter CW. Antibody responses and protection in mice immunized with Herpes simplex virus type 1 antigen immune stimulating complexes preparations. J. Gen. Virol. 1989; 70: 2149-55.
62. Ertürk M, Jennings R, Philpotts RJ, Potter CW. Biochemical characterization of Herpes simplex virus type-1-immunostimulating complexes (ISCOMs): A multi-glycoprotein structure. Vaccine 1991; 9: 668-74.
63. Höglund S, Åkerblom L, Özel M et al. Characterization of immunostimulating complex (ISCOM) of HIV-1. Viral Immunol. 1990; 3: 195-206.
64. Åkerblom L, Vilacres M. HIV ISCOMS: A vaccine model. In: Tenth Scandinavian Virus Symposium Proceedings, Umea, pp. 72.
65. Cox JC, Coulter AR. Advances in adjuvant technology and applications. In: Wong WK (ed.) Animals Parasite Control Utilizing Technology. Boca Raton: CRC Press, 1992; 49-112.
66. Watson D, Watson N, Fossum C, Lövgren K, Morein B. Interactions between immune-stimulating complexes (ISCOMS) and peritoneal mononuclear leucocytes. Microbiol. Immunol. 1992; 36: 199-203.
67. Villacrés-Erickson M. Induction of immune response by Iscoms. PhD thesis, Swedish University of Agricultural Science, 1993.
68. Morein B, Villacrés-Eriksson M, Åkerblom L, Rönnberg B, Lövgren K, Sjölander A. Mechanisms behind the immune response induced by immunostimulating complexes. Aids Res. Human Retroviruses 1994; 10: S109-14.
69. Jiang W, Swiggard WJ, Heufler C et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151-5.
70. Watson DL, Lövgren K, Watson NA, Fossum C, Morein B, Höglund S. The inflammatory response and antigen localization following immunization with influenza virus iscoms. Inflammation 1989; 13: 641-9.
71. Speijers GPA, Danse LHJC, Beuvry EC, Strik J, Vos JG. Local reactions of the saponin Quil A containing iscom measles vaccine after intramuscular injection of rats: A comparison with the effect of DPT-Polio vaccine. Fundamen. App. Toxicol. 1988; 10: 425-30.
72. Fossum C, Bergström M, Lövgren K, Watson DL, Morein B. Effect of iscom and/or their adjuvant moiety (matrix) on the initial proliferative and IL-2 responses in vitro. Comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell. Immunol. 1990; 129: 414-25.
73. Van Binnendijk RS, van Baalen CA, Poelen MCM et al. Measles virus transmembrane fusion protein synthesized de novo or presented in iscom is endogenously processed for HLA class I-and class II-restricted T cell recognition. J. Exp. Med. 1992; 176: 119-28.
74. Harding CV, Collins DS, Kanagawa O, Unanue E. Liposome encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol. 1991; 147: 2860-3.
75. De Vries P, Van Binnendijk RS, van der Marel P et al. Measles virus fusion protein presented in an immunestimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. J. Gen. Virol. 1988; 69: 549-59.
76. Lövgren K. The serum antibody responses distributed in subclasses and isotypes following intranasal and subcutaneous immunization with influenza virus iscoms. Scand. J. Immunol. 1988; 2: 241-5.
77. Ben-Ahmeida ET, Potter CW, Gregoriadis G, Adithan C, Jennings R. IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines. J. Med. Microbiol. 1994; 40: 261-9.
78. Robinson K, Bellaby T, Wakelin D. Vaccination against the nematode Trichenella spiralis in high and low responder mice. Effects of different adjuvants, protective immunity and immune response. Immunol. 1994; 82: 261-7.
79. Bakouche O, Mougin B, Gerlier D. In vitro cellular immune response to measles viral glycoproteins: role of the antigen vector. Immunol. 1987; 62: 605-11.
80. + T cell clones specific for the major envelope glycoproteins gp 340. Eur. J. Immunol. 1988; 18: 1689-97.
81. Flebbe LM, Bradley-Mullen H. Immunopotentiating effects of the adjuvants SGP and Quil A. Cell. Immunol. 1986; 99: 119-27.
82. Flebbe LM, Bradley-Mullen H. Immunopotentiation by SGP and Quil A. Cell. Immunol. 1986; 99: 128-39.
83. + cytotoxic T cells by immunization with purified HIV-1 envelope proteins in iscoms. Nature 1990; 344: 873-5.
84. Lövgren K, Kȧberg H, Morein B. An experimental influenza subunit vaccine (ISCOM)-induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin. Exp. Immunol. 1990; 82: 435-9.
85. Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunised with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 1994; 153: 4029-39.
86. Ben Ahmeida ETS, Gregoriadis G, Potter CW, Jennings R. Immunopotentiation of local and systemic immune responses by ISCOMs, liposomes and FCA: Role in protection against influenza A in mice. Vaccine 1993; 11: 1302-9.
87. Trudel M, Nandon F, Séguin C, Brault S, Lusignan Y, Lemieux S. Initation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine. 1992; 10: 107-112.
88. Ghazi HO, Potter CW, Smith TL, Jennings R. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMS. J. Med. Microbiol. 1995; 42: 53-61.
89. Snodgrass DR, Campbell I, Mwenda JM et al. Stimulation of rotavirus IgA, IgG and neutralizing antibodies in baboon milk by parenteral vaccination. Vaccine 1995; 13: 408-13.
90. Åkerblom L, Strömstedt K, Höglund S, Osterhaus A, Morein B. Formation and characterization of FeLV iscoms. Vaccine 1989; 7: 141-5.
91. Dalsgaard K, Hilgers L, Trouve G. Classical and new approaches to adjuvant use in domestic food animals. Advan. Vet. Sci. Comp. Med. 1990; 35: 121-60.
92. Morein B, Fossum C, Lövgren K, Höglund S. The iscom - a modern approach to vaccines. Sem. Virol. 1990; 1: 49-55.
93. Mowat A, Maloy KJ, Donachie AM. Immune stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunol. 1993; 80: 527-34.
94. Ben Ahmeida ETS, Jennings R, Erturk M, Potter CW. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as iscoms. with FCA, ALH or as infectious virus. Arch. Virol. 1992; 125: 71-86.
95. Osterhaus A, DeVries P, Morein B, Åkerblom L, Heeney J. SIV-specific protective immunity in macaques vaccinated with SIV iscom or MDP adjuvanted whole inactivated SIV. Aids Res. Human Retroviruses 1992; 8: 1507-10.
96. Levi M, Rudén U, Birx D et al. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. J. Acquired Immune Deficiency Syndromes. 1993; 6: 855-64.
97. Puentes E, Cancio E, Erias A et al. Efficiency of various non-oily adjuvants in immunization against Aujeszky's Disease (Pseudorabies) virus. J. Vet. Med. B. 1993; 40: 353-65.
98. De Vries P, Heeney JL, Boes J et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994; 12: 1443-54.
99. Stieneker F, Kersten G, van Bloois L et al. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 1995; 13: 45-53.
100. + T cell receptor alpha, beta cytotoxic T lymphocytes of peptides in the self and mycobacterial hsp60 which share intermediate sequence homology. Eur. J. Immunol. 1995; 25: 451-8.
101. Maloy KJ, Donachie AM, O'Hagan DT, Mowat A. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunol. 1994; 81: 661-7.
102. + cytotoxic T lymphocyte responses. J. Immunol. 1992; 148: 2357-62.
103. Raychaudhuri S, Tonks M, Carbone F et al. Induction of antigen specific class I restricted cytotoxic T cells by soluble proteins in vivo. Proc. Natl Acad. Sci. USA 1992; 89: 8308-12.
104. Dilon SB, Demuth SG, Schneider MA et al. Induction of protective class I MHC-restricted CTL in mice by recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine 1992; 10: 309-17.
105. Zhou F, Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 1993; 11: 1139-44.
106. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989; 342: 561-4.
107. Vogel FR. The role of adjuvants in vaccine design. Proceedings IBC 2nd Annual Conference on New Advances in Vaccine Technologies and Applications. Bethesda, MD., USA.
108. Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR. Safety evaluation of vaccine adjuvants: National cooperative vaccine development meeting working group. Aids Res. Retroviruses 1993; 9: Suppl. 1: S47-51.
109. Vogel FR. The role of adjuvants in retroviral vaccines. Int. J. Immunopharmac. 1995; 17: 85-90.
110. The European Concerted Action on 'Macaque Models for AIDS Research'. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: Comparison of adjuvants, doses and challenge viruses. Vaccine 1995; 3: 295-300.
111. Straus SE, Corey L, Burke RL et al. Successful immunotherapy of genital herpes with a recombinant Herpes simplex type 2 glycoprotein D vaccine: Results of a placebo-controlled trial. Lancet 1994; 343: 1460-3.
112. Burke RL, Goldenthal L, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J. Infect. Dis. 1994; 170: 1110-19.
113. Gisler RH, Schumann G, Sackman W, Pericin W, Tarscay L, Dietrich FM. A novel muramyl peptide, MTP-PE: Profile of biological activities. In: Yamamura Y, Kotanis (eds) Immunomodulatory Microbiol Products and Related Synthetic Compounds. Amsterdam: Excerpta Medica, 1982; 167-70.
114. Ribi E, Cantrell JL, Takayama K, Qureshi N, Petersen J, Ribi HO. Lipid A and immunotherapy. Rev. Infect. Dis. 1984; 6: 567-72.
115. Alison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell mediated immunity. J. Immunol. Methods 1986; 95: 157-68.
116. Prieels JP, Garcon Johnson N, Slaoui M, Pietro P. Vaccine composition containing adjuvants. Patent application, WO94/00153.
117. Hoth DF, Bolognesi DP, Corey L, Vermund SH. HIV vaccine development: A progress report. Ann. Intern. Med. 1994; 8: 603-11.
118. Morein B, Åkerblom L. The Iscom - An Approach to subunit vaccines. In: Isaacson RE (ed.) Recombinant DNA Vaccines. Rationale and Strategy. New York: Marcel Dekker, 1992; 369-86.
119. Morein B, Lövgren K. Pharmaceutical carrier. Patent application, WO92/21331.
120. Bjorkman C, Lunden A, Holmdahl J, Barber J, Trees AJ, Uggla A. Neospora cannium in dogs: Detection of antibodies by ELISA using an ISCOM antigen. Parasite Imm. 1994; 16: 643-8.
121. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993; 11: 293-306.
122. Osterhaus A, Weijer K, Uytde-Haag F, Jarret O, Sundquist B, Morein B. Induction of protective immune response in cats by vaccination feline leukaemia virus iscom. J. Immunol. 1985; 135: 591-6.
123. Kensil CA, Marciani DJ, Belz GA, Hung CH. Saponin adjuvant. Patent application, WO88/09336.
124. Putkonen P, Björling E, Åkerblom L et al. Long-standing protection of Macaques against HIV-2 with a HIV-2 iscom vaccine. J. Acquired Immune Deficiency Syndromes 1994; 7: 551-9.
125. Mumford JA, Jesset D, Dunleavy U et al. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 1994; 12: 857-63.
126. Mumford JA, Jesset D, Rollinson EA, Hannant D, Draper ME. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Vet. Record 134: 158-62.
127. Kodiahalli S, Sivanadan V, Nagaraja KV, Shaw D, Halvorson DA. A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection. Vaccine 1994; 12: 1467-72.
128. Erturk M, Hill TJ, Shimeld C, Jennings R. Acute and latent infection of mice immunized with HSV-1 ISCOM vaccine. Arch. Virol. 1992; 125: 87-101.
129. Visser IKG, Vedder EJ, van de Bildt MWG, Örvell C, Barrett T. Osterhaus ADME. Canine distemper virus Iscoms induce protection in harbour seals (Phoca vitulina) against phocid distemper but still allow subsequent infection with phocid distemper virus-1. Vaccine 1992; 10: 435-8.
130. Fohlman J, Pauksen K, Morein B, Bjare U, Ilbäck NG, Friman G. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand. J. Infect. Dis. Suppl. 1993; 88: 103-8.
131. Hannant D, Jessett DM, O'Neill T, Dolby CA, Cook RF, Mumford JA. Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. Res. Vet. Sci. 1993; 54: 299-305.
132. Tulman ER, Garmendia AE. Delivery of pseudorabies virus envelope antigens in immunostimulating complexes (ISCOMs): Elicitation of neutralizing antibody responses in swine and protection in mice. Vaccine 1994; 12: 1349-54.
133. York IA, Thorsen J. Evaluation of a subunit vaccine for bovine adenovirus type 3. Am. J. Vet. Res. 1992; 53: 180-3.
134. Charles SD, Nagaraja KV, Sivanandan V. A lipid-conjugated immunostimulating complex subunit vaccine against Salmonella infection in turkeys. Avian Dis. 1993; 37: 477-84.
135. Charles SD, Hussain I, Choi CV, Nagaraja KV, Sivanandan V. Adjuvanted subunit vaccines for the control of Salmonella enteritidis infection in turkeys. Am. J. Vet. Res. 1994; 55: 636-42.
136. Golovliov I, Ericsson M, Åkerbloom L, Sandström G, Tarnivik A, Sjöstedt A. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine 1995; 13: 261-7.
137. Lockyer MJ, Cooper H, Tite J, Rowan W, Crowe JS. Immunogenicity of a hybrid Plasmodium falciparum malaria antigen. Parasitology 1993; 106: 451-7.
138. Sjölander A, Hansson M, Lövgren K, Wåhlin B, Berzins K, Perlmann P. Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen PH55/RESA. Parasite Immunol. 1993; 15: 355-9.
139. Sjölander A, Ståhl S, Lövgren K et al. Plasmodium Falciparum: The immune response in rabbits to the clustered-arginine-rich-protein (CARP) after immunization in Freund's adjuvant or immunostimulating complexes (ISCOMs). Exp. Parasitology. 1994; 76: 134-45.
140. Lundén A, Lövgren K, Uggla A, Araujo F. Immune responses and resistance to Toxoplasma gondili in mice immunized with antigens of the parasite incorporated into immunostimulating complexes. Infect. Immun. 1993; 61: 2639-43.
141. Jackson LA, Opdebeeck JP. Quil A and ISCOM as adjuvants for midgut membrane antigens of Boophilus microplus. App. Parasitology 1994; 35: 87-98.
142. SF2gp120 subunit vaccine combined with MF59 adjuvant without muramyl tripeptide dipalmitoyl phoshatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 1994; 170: 1288-91.
143. Keitel W, Couch R, Bond N, Adair S, Van Nest G, Deckker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993; 11: 909-13.
144. Livingston PO, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12: 1275-80.
145. Mitchell MS, Harel W, Kempf RA et al. Active-specific immunotherapy for melanoma. J. Clin. Oncol. 1990; 8: 856-69.
146. Schulz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Ables G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995; 13: 503-8.
147. MacLean GD, Bowen-Yacyshyn MB, Samuel J et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 1992; 11: 292-305.
148. Fries LF, Gordon DM, Richards RL et al. Liposomal malaria vaccine in humans. A safe and potent adjuvant strategy. Proc. Natl Acad. Sci. USA 1992; 89: 358-62.
149. Wintsch J, Chaignat CL, Braun DG et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis. 1991; 163: 219-25.
150. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344: 160-3.
151. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995; 13: 891-3.
152. Scheepers K, Becht H. Protestion of mice against an influenza virus infection by oral vaccination with viral nucleo-protein incorporated in immunostimulating complexes. Med. Microbiol. Imm. 1994; 183: 265-78.